AbbVie Q2 adj EPS $2.65, revenue $14.46B; raises FY2024 adj EPS guidance to $10.71-$10.91

AbbVie Inc.

2024-Q2 EPS reported $1.53 revenue$26,772,000,000

Q2 GAAP EPS $0.77 (down 32.5% YoY); adjusted EPS $2.65 (down 8.9% YoY), including $0.52 IPR&D impact.
Net revenue $14.462B (+4.3% reported, +5.6% operational); Immunology up 2.3% as Humira -29.8% offset by Skyrizi +44.8% and Rinvoq +55.8%.
Neuroscience portfolio up 14.7% to $2.162B; Aesthetics flat at $1.390B.
FY2024 adjusted EPS guidance raised to $10.71-$10.91 from $10.61-$10.81, including $0.60 IPR&D impact.
Recent events: Robert Michael became CEO July 1; FDA approved Skyrizi for UC; FDA CRL for ABBV-951 Parkinson's; acquisitions of Landos and Celsius.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.